JKJavad Khanali

Javad Khanali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Javad Khanali has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of intra-peritoneal administration of amnion gel and low-level laser therapy in the prevention of postoperative intra-abdominal adhesion formation in rat model

    by Roya Derakhshan, Mazyar Banibashar, Yasamin Ostadi, Javad Khanali, Mohammad Bayat, Houssein Ahmadi, Reza Khanali, Behrang Kazeminejad, Babak Sabet

  • Open Access

    The synergistic regenerative and anti-inflammatory effects of Ponesimod and amniotic epithelial stem cells in the Cuprizone animal model of multiple sclerosis

    by Fahimeh Safaeinejad, Javad Khanali, Yasamin Ostadi, Maryam Salimi, Nasim Vousooghi, Shima Davoudi, Asma Manzari-Tavakoli, Hassan Niknejad

  • Open Access

    Injectable extracellular matrix microparticles for regenerative and biocompatible soft tissue augmentation

    by Javad Khanali, Yasamin Ostadi, Fatemeh A. Tehrani, Tahereh Tayebi, Roghayeh Tarasi, Younes Yassaghi, Yasaman Nazerian, Maryam Salimi, Feizollah Niazi, Soheyl Bahrami, et al.

    Decellularized extracellular matrices (DEMs) have been widely investigated as promising biomaterials for soft tissue augmentation. In contrast, the use of decellularized human amniotic membrane (dHAM) represents a novel approach within this field, offering unique potential for clinical application. The objective of this study is to develop an “off-the-shelf” bioactive soft tissue filler from crosslinked and non-crosslinked dHAM in the injectable microparticle formulation. We used physical and enzymatic processes for decellularization and milling for fabricating the injectable matrix. The decellularization, crosslinking and detoxification protocol removed immunogenic cellular components, preserved collagen and glycosaminoglycan content, and reduced residual crosslinker to sub-cytotoxic levels. Consequently, both crosslinked and non-crosslinked powder extractions promoted cell viability and proliferation and did not affect cell migration in culture. Moreover, the crosslinked powder showed higher stability upon in vitro enzymatic degradation and prolonged volume retention in the subcutaneous guinea pig model. Histopathologic evaluation of the implants showed that immune cell infiltration markedly resolved over the 12-week study period. Moreover, immunohistochemistry staining for CD68 and CD163 macrophage markers indicated the abundance of CD163-positive cells, commonly associated with an anti-inflammatory or M2-like phenotype. Staining for CD31 endothelial cell marker demonstrated the formation of blood vessels with intraluminal RBCs and endothelial cell lining within the implants, which is indicative of neovascularization. Therefore, dHAM demonstrated long-term volume retention, reduced immune cell infiltration, and was associated with a CD163-positive macrophage phenotype and evidence of vascularization in the animal model. This study suggests dHAM as a readily deliverable biomaterial and a promising candidate to address clinical translational needs for soft tissue reconstruction.

  • Comparison of simvastatin gel and amnion membrane gel for preventing postoperative intra-abdominal adhesion formation in rat model

    by Forouheh Moazezi, Roya Derakhshan, Yasamin Ostadi, Javad Khanali, Seyed Ali Ziai, Mohammad Abbas Sheikholeslami, Alireza Heydarnejad, Behrang Kazemnejad, Babak Sabet


  • Open Access

    Global, regional, and national quality of care index of cervical and ovarian cancer: a systematic analysis for the global burden of disease study 1990–2019

    by Mohammadreza Azangou-Khyavy, Erfan Ghasemi, Negar Rezaei, Javad Khanali, Ali-Asghar Kolahi, Mohammad-Reza Malekpour, Mahsa Heidari‐Foroozan, Maryam Nasserinejad, Esmaeil Mohammadi, Mohsen Abbasi-Kangevari, et al.

    Background and objective: Cervical cancer is the most preventable and ovarian cancer is the most lethal gynecological cancer. However, in the world, there are disparities in health care performances resulting in differences in the burden of these cancers. The objective of this study was to compare the health-system quality of care and inequities for these cancers using the Quality of Care Index (QCI). Material and methods: The 1990–2019 data of the Global Burden of Disease (GBD) was analyzed to extract rates of incidence, prevalence, mortality, Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLL), and Years of healthy life lost due to disability (YLD) of cervical and ovarian cancer. Four indices were developed as a proxy for the quality of care using the above-mentioned rates. Thereafter, a Principal Components Analysis (PCA) was applied to construct the Quality of Care Index (QCI) as a summary measure of the developed indices. Results: The incidence of cervical cancer decreased from 1990 to 2019, whereas the incidence of ovarian cancer increased between these years. However, the mortality rate of both cancers decreased in this interval. The global age-standardized QCI for cervical cancer and ovarian cancer were 43.1 and 48.5 in 1990 and increased to 58.5 and 58.4 in 2019, respectively. QCI for cervical cancer and ovarian cancer generally decreased with aging, and different age groups had inequitable QCIs. Higher-income countries generally had higher QCIs for both cancers, but exceptions were also observed. Conclusions: Uncovering disparities in cervical and ovarian cancer care across locations, Socio-Demographic Index levels, and age groups necessitate urgent improvements in healthcare systems for equitable care. These findings underscore the need for targeted interventions and prompt future research to explore root causes and effective strategies for narrowing these gaps.


  • Decellularized Extracellular Matrix Scaffolds for Soft Tissue Augmentation: From Host–Scaffold Interactions to Bottlenecks in Clinical Translation

    by Yasamin Ostadi, Javad Khanali, Fatemeh A. Tehrani, Ghasem Yazdanpanah, Soheyl Bahrami, Feizollah Niazi, Hassan Niknejad

    Along with a paradigm shift in looking at soft tissue fillers from space-filling to bioactive materials, decellularized extracellular matrix (DEM) fillers have gained more attention considering their superior bioactivity. However, the complex mechanisms that govern the interaction between host tissues and DEMs have been partially understood. This review first covers the mechanisms that determine immunogenicity, angiogenesis and vasculogenesis, and recellularization and remodeling after DEM implantation into host tissue, with a particular focus on related findings from filler materials. Accordingly, the review delves into the dual role of macrophages and their M1/M2 polarization paradigm to form both constructive and destructive immune responses to DEM implants. Moreover, the contribution of macrophages in angiogenesis has been elucidated, which includes but is not limited to the secretion of angiogenic growth factors and extracellular matrix (ECM) remodeling. The findings challenge the traditional view of immune cells as solely destructive entities in biomaterials and indicate their multifaceted roles in tissue regeneration. Furthermore, the review discusses how the compositional factors of DEMs, such as the presence of growth factors and matrikines, can influence angiogenesis, cell fate, and differentiation during the recellularization process. It is also shown that the biomechanical properties of DEMs, including tissue stiffness, modulate cell responses through mechanotransduction pathways, and the structural properties of DEMs, such as scaffold porosity, impact cell–cell and cell–ECM interactions. Finally, we pointed out the current clinical applications, the bottlenecks in the clinical translation of DEM biomaterials into soft tissue fillers, as well as the naïve research areas of the field.


  • Open Access

    Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study

    by Maryam Sahlolbei, Mohammadreza Azangou-Khyavy, Javad Khanali, Babak Khorsand, Aref Shiralipour, Naser Ahmadbeigi, Zahra Madjd, Hossein Ghanbarian, Alireza Ardjmand, Seyed Mahmoud Hashemi, et al.


  • Open Access

    Omicron-Specific and Bivalent Omicron-Containing Vaccine Candidates Elicit Potent Virus Neutralisation in the Animal Model

    by Asghar Abdoli, Hamidreza Jamshidi, Mohammad Taqavian, Mehdi Lari Baghal, Hasan Jalili, Javad Khanali, Mohammadreza Azangou-Khyavy, Mohsen Abbasi-Kangevari, Seyyed-Hadi Ghamari, Mohammad-Reza Malekpour

    Background: Omicron variant (B. 1.1.529) is able to escape from naturally acquired and vaccine-induced immunity, which mandates updating the current COVID-19 vaccines. Here, we investigated and compared the neutralising antibody induction of the ancestral variant-based BIV1-CovIran vaccine, the Omicron variant-based BIV1-CovIran Plus vaccine, and the novel bivalent vaccine candidate, BBIV1-CovIran, against the Omicron and ancestral Wuhan variants on the rat model. Methods: Viruses were isolated from a clinical specimen and virus characterisation performed. After inactivating the viral particles, the viruses were purified and formulated. Bivalent vaccines were a composition of 2.5 μg (5 μg total) or 5 μg (10 μg total) doses of each ansectral-based and Omicron-based monovalent vaccine. Subsequently, the potency of the monovalent and bivalent vaccines was investigated using the virus neutralisation test (VNT). Results: The group that received three doses of the Omicron-specific vaccine demonstrated neutralisation activity against the Omicron variant with a geometric mean titer of 337.8. However, three doses of the Wuhan variant-specific vaccine could neutralise the Omicron variant at a maximum of 1/32 serum dilution. The neutralisation activity of the Omicron-specific vaccine, when administered as the booster dose after two doses of the Wuhan variant-specific vaccine, was 100% against the Omicron variant and the Wuhan variant at 1/64 and 1/128 serum dilution, respectively. Three doses of 5 μg bivalent vaccine could effectively neutralise both variants at the minimum of 1/128 serum dilution. The 10 μg bivalent vaccine at three doses showed even higher neutralisation titers: geometric mean titer of 338.0 against Omicron and 445.7 against Wuhan). Conclusion: It is shown that the candidate bivalent vaccine could elicit a potent immune response against both Wuhan-Hu-1 and Omicron BA.1 variants. Therefore, we plan to evaluate the updated vaccine in the clinical trial setting.


  • Open Access

    Global, regional, and national quality of care of gallbladder and biliary tract cancer: a systematic analysis for the global burden of disease study 1990–2017

    by Javad Khanali, Mohammad-Reza Malekpour, Mohammadreza Azangou-Khyavy, Sahar Saeedi Moghaddam, Negar Rezaei, Ali-Asghar Kolahi, Mohsen Abbasi-Kangevari, Esmaeil Mohammadi, Nazila Rezaei, Moein Yoosefi, et al.

    Background: To improve health outcomes to their maximum level, defining indices to measure healthcare quality and accessibility is crucial. In this study, we implemented the novel Quality of Care Index (QCI) to estimate the quality and accessibility of care for patients with gallbladder and biliary tract cancer (GBBTC) in 195 countries, 21 Global Burden of Disease (GBD) regions, Socio-demographic Index (SDI) quintiles, and sex groups. Method: This cross-sectional study extracted estimates on GBBTC burden from the GBD 2017, which presents population-based estimates on GBBTC burden for higher than 15-year-old patients from 1990 to 2017. Four secondary indices indicating quality of care were chosen, comprising Mortality to incidence, Disability-Adjusted Life Year (DALY) to prevalence, prevalence to incidence, and years of life lost (YLL) to years lived with disability (YLD) ratios. Then, the whole dataset was analyzed using Principal Component Analysis to combine the four indices and create a single all-inclusive measure named QCI. The QCI was scaled to the 0–100 range, with 100 indicating the best quality of care among countries. Gender Disparity Ratio (GDR) was defined as the female to male QCI ratio to show gender inequity throughout the regions and countries. Results: Global QCI score for GBBTC was 33.5 in 2017, which has increased by 29% since 1990. There was a considerable gender disparity in favor of men (GDR = 0.74) in 2017, showing QCI has moved toward gender inequity since 1990 (GDR = 0.85). Quality of care followed a heterogeneous pattern among regions and countries and was positively correlated with the countries’ developmental status reflected in SDI (r = 0.7; CI 95%: 0.61–0.76; P value< 0.001). Accordingly, High-income North America (QCI = 72.4) had the highest QCI; whereas, Eastern Sub-Saharan Africa (QCI = 3) had the lowest QCI among regions. Patients aged 45 to 80 had lower QCI scores than younger and older adults. The highest QCI score was for the older than 95 age group (QCI = 54), and the lowest was for the 50–54 age group (QCI = 26.0). Conclusions: QCI improved considerably from 1990 to 2017; however, it showed heterogeneous distribution and inequity between sex and age groups. In each regional context, plans from countries with the highest QCI and best gender equity should be disseminated and implemented in order to decrease the overall burden of GBBTC.


  • Open Access

    National and Subnational Cancer Incidence for 22 Cancer Groups, 2000 to 2016: A Study Based on Cancer Registration Data of Iran

    by Javad Khanali, Ali-Asghar Kolahi

    Background. Cancer is an increasing public health concern, and detailed knowledge of the cancer incidence is required for developing effective cancer control plans. The objective of this study is to present the cancer incidence of 22 cancer groups in Iran and all 31 provinces of the country from 2000 to 2016, for both sexes across different age groups. Method. To study the national and provincial cancer incidence in Iran, we extracted data from the Cancer Project, which collects the Iranian cancer registry data and visualizes it in the VIZIT data visualization system. The methodology and statistical analysis that is used in this study follow the cancer project study protocol. Joinpoint analysis was performed to calculate the average annual percent change of the crude rates and age-standardized rates from 2000 to 2016. Results. Cancer incidence was 126,982 patients in 2016, and the crude rate (CR) of cancer in both sexes and all ages was 155 per 100,000 people. Cancer incidence approximately doubled between 2000 and 2016; however, the age-standardized rate (ASR) had a less drastic increase. The most incident cancers in 2016 were breast, skin, and colorectal cancers; however, the ranking of cancer groups by incidence was different in different age and sex groups and provinces. Some cancers exhibited a unique distribution pattern in the country with high-incidence local areas. Discussion. The study showed that cancer incidence, crude rate, and age-standardized rate (ASR) in Iran had increased in 2000-2016 with vast heterogeneity by cancer type, province, and sex. Moreover, it was shown that the crude rate of cancer in Iran was much less than the global cancer crude rate. Providing such data helps to allocate resources and develop effective national cancer control plans appropriately.